What question did this study set out to answer?

P0738Real-world experience of switching from intravenous to subcutaneous infliximab in pediatric Inflammatory Bowel Disease patients: a multicenter retrospective cohort from the Canary Islands, Spain.

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study assesses safety and effectiveness of switching infliximab routes in children, suggesting a viable alternative.

To evaluate the effectiveness and safety of switching from intravenous to subcutaneous infliximab in pediatric inflammatory bowel disease patients.
Retrospective multicenter cohort study
Included patients under 18 who switched from intravenous to subcutaneous infliximab
Clinical indices and biomarkers were assessed at baseline, 3, 6, and 12 months
100% clinical remission maintained after switching
Significant improvement in PCDAI scores at 3 months
Stable trough infliximab levels throughout follow-up
No adverse events or treatment discontinuations reported

Alberto et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark